

## Rilotumumab

Cat. No.:	HY-P99217
CAS No.:	872514-65-3
Target:	c-Met/HGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research <sup>[1][2]</sup> .	
In Vitro	Rilotumumab (10 µg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis <sup>[2]</sup>	
	Cell Line:	U87MG.vIII cells
	Concentration:	10 µg/mL
	Incubation Time:	Overnight
	Result:	Showed MET phosphorylation at tyrosine residue 1234 (Y1234) and Y1235 ~50% lower in U87MG.vIII cells than in untreated cells. Showed an increase in total MET compared with untreated cells.
In Vivo	Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells <sup>[2]</sup>
	Dosage:	1.5 mg/kg
	Administration:	Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
	Result:	Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).

### REFERENCES

---

[1]. Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24.

[2]. Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA